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Amsterdam-Defined Asian HNPCC Patients: 
Data From the Singapore Polyposis Registry
P Po oh h- -K Ko oo on n   K Ko oh h, , Min-Hoe Chew, Carol Loi, Choong-Leong Tang,
Kong-Weng Eu
Singapore Polyposis Registry & Department of Colorectal Surgery, Singapore General
Hospital, Outram Road, Singapore (169 608)
K Ke ey y   w wo or rd ds s: :   Asians, HNPCC, Amsterdam criteria
B Ba ac ck kg gr ro ou un nd d: : Routine genetic testing is costly and
not widely available in Asia. A thorough family history
remains the most important and cost-effective means
of diagnosing hereditary non-polyposis colorectal
cancer (HNPCC). However, the usefulness of the
Amsterdam criteria for diagnosis of HNPCC in Asians
has not been thoroughly evaluated. This study aims to
characterize the phenotype of Amsterdam-defined
Asian HNPCC patients registered with the Singapore
Polyposis Registry since 1989.
M Me et th ho od ds s: : A review was conducted of HNPCC
patients registered with the Singapore Polyposis Registry
over a 16-year period. All patients fulfilled the
Amsterdam I and II criteria. Data on demographics, site
of colorectal cancers, synchronous cancers, associated
extra-colonic cancers in pedigrees, histology, type of
colonic resections, Dukes’ and TNM staging were
obtained from a prospective computerized database.
R Re es su ul lt ts s: :   A total of 52 patients with colorectal cancer
from Amsterdam-defined HNPCC families were
reviewed. The male to female ratio was 1.6:1 with
median age of 44.5 years (range 27-73) at diagnosis
of first cancer. The ethnic distribution was 47 Chinese
(91%) and 5 Malays (9%), and the median follow up
was 44.9 months (range 2-183 months). More than
two thirds (69%) of the tumours were left-sided, with
the majority located in the sigmoid colon. More than
half (60%) of the tumours presented at a late stage
(Dukes’ C&D), with 83% being moderately or poorly
differentiated adenocarcinomas. Left-sided tumours
tend to have more advanced Duke’s stage disease
(p=0.096) and a higher rate of metastasis (p=0.08)
compared to right-sided lesions. There was, however,
no significant difference in disease-free or overall
survival between left and right-sided tumours.
C Co on nc cl lu us si io on ns s: : In contrast to data from studies on
Caucasian populations, Amsterdam-defined Asian
HNPCC families appeared to have more left-sided
tumours. These differences may be due to inadequacies
of the Amsterdam criteria when applied to an Asian
population or a true ethnic variation in HNPCC
phenotypic expression. Further studies are needed to
clarify the genotypic-phenotypic correlations and the
usefulness of the Amsterdam criteria in diagnosis of
HNPCC in Asian populations.
[2]
Endoscopic Surveillance and Surgical Intervention Can Reduce
Duodenal Malignancy in Familial Adenomatous Polyposis (FAP)
Patients
R R. .   M Ma ac ck ke ey y
1, M. Johnson
1, N. Brown
1, C. Burke
2, J. Church
3,
R.M. Walsh
1
1Department of General Surgery; 2Department of Gastroenterology; 3Department of Colorectal
Surgery, Cleveland Clinic, 9500 Euclid Avenue, General Surgery/A80, Cleveland, Ohio, 44195
K Ke ey y   w wo or rd ds s: : familial adenomatous polyposis, duodenal
adenomas, pancreas-sparing duodenectomy
B Ba ac ck kg gr ro ou un nd d: : Endoscopic surveillance and Spigelman
classification is used to determine the need for surgical
resection.
M Me et th ho od ds s: : FAP patients undergoing surveillance and
surgical intervention over the past 15 years were reviewed.
R Re es su ul lt ts s: : One-hundred sixty-three patients underwent
upper endoscopic surveillance. Eighty-four patients were
male and the mean age was 48.3±14.4 years. Six-
hundred ninety-six endoscopies were performed,
averaging 5.7 per patient with a mean follow-up of
100.6 months. Spigelman stage III/IV was present in 53
(33%) patients at initial endoscopy. During endoscopic
surveillance 11/64 (17%) stage I and 18/39 (46%) 
stage II patients progressed to Spigelman III/IV, over a mean
of 10.5 and 7.6 years, respectively. Thirty patients (18%)
underwent endoscopic therapy: 11 endoscopic polypecto-
mies (EP), 14 argon/electro-coagulation (APC) and 
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5 combined. Ten patients went on to surgical intervention.
One patient was downstaged from Spigelman IV to II
after 17 combined endoscopic procedures. There were
5 endoscopic related complications (0.7%) in the surveil-
lance group: 2 duodenal perforations, one ileus, one
pancreatitis, and one post-procedural abdominal pain.
Forty-seven operations were performed for Spigelman
III/IV polyposis: 30 pancreas-sparing duodenectomies
(PSD), 10 pancreaticoduodenectomies (PD), 4 segmental
and 3 transduodenal resections. There was no peri-
operative mortality and 23 patients had 30 complications:
10 patients (22%) with delayed gastric emptying, 8 (17%)
with bilio-pancreatic leak, 4 (9%) re-operations. Six
patients (4 PD, 1 PSD, 1 Segmental) had carcinoma at
operation, 2 known pre-operatively. Post-operative mean
follow-up was 45.8 months. Adenomas recurred in 
10 patients (4 advanced limb, 6 remnant duodenum);
all have been managed endoscopically. Eight patients
(5%) died during surveillance, 3 FAP related.
C Co on nc cl lu us si io on ns s: : Endoscopic surveillance is valuable
for monitoring stage migration and timing of surgical
intervention. Complete duodenectomy is the preferred
treatment for advanced polyposis.
[3]
Falling Through the Crack: Potential Missed Lynch Syndrome
J Ju ul li ia an n   S Sa an nc ch he ez z, , Jon Vogel, Matthew Kalady, James Church
Department of Colorectal Surgery, Cleveland Clinic Foundation, Cleveland, Ohio 44195
K Ke ey y   w wo or rd ds s: : Lynch syndrome, microsatellite instability,
Bethesda criteria
B Ba ac ck kg gr ro ou un nd d: : The Amsterdam Criteria (AC) and
Bethesda Guidelines (BG) are clinical and pathological
tools that are used to identify Lynch syndrome (LS)
patients. A family history of LS-related cancers,
histopathology suggestive of microsatellite instability
(MSI-H), or confirmation of MSI-H in a patient with
colorectal cancer should prompt an appropriate
response by the pathologist and surgeon. This study
evaluates the impact of pathology findings and MSI-H
status on LS evaluation by the pathologist and surgeon.
M Me et th ho od ds s: : MSI-H tumors were identified from 
a single institution frozen tissue bank, and MLH-1
methylation was determined by MethyLight quantitative
PCR. Clinical information including demographics,
histopathology, and personal and family cancer history
was recorded. Subsequent recommendations by the
pathologist and surgeon for surveillance, genetic
testing, counseling, and family risk evaluation were
collected from the medical record.
R Re es su ul lt ts s: : 69 patients with MSI-H tumors were identified
between 2000-2007. The median age at resection was
73 years (34-89 years), 48% were female, and 81% 
of tumors localized to the right colon. 17 (25%) patients
were appropriately referred for additional testing including
8 of 9 with MSI-H like histology and 9 of 60 without 
MSI-H documentation by the pathologist (Table 1). 
52 (75%) patients with MSI-H tumors escaped detection
by pathologists and surgeons and no additional workup
for LS was performed. MSI-H like histology was the most
influential factor for further testing, as 89% of those
patients had subsequent LS investigation. 34 (49%) of the
MSI-H tumors showed no methylation at MLH-1,
including 4 patients who met AC, had MSI-H like
histology, but had no further LS testing (Table 1).
C Co on nc cl lu us si io on ns s: : These data show that MSI-H like
histology was the driving force for the evaluation of LS.
Histopathology alone failed to identify all potential LS
patients. Omission of an adequate familial risk
assessment may lead to missed diagnosis of LS when
the presence of MSI-H like histology fails to trigger
appropriate testing. Our findings underscore the
importance of adequate familial risk assessment in the
identification of patients with LS and the importance of
further testing when MSI-H like histology is present.
[4]
Down-Regulation of the Growth-Suppressor Gene CDK2-AP1 
in MSI CRC is Confirmed in Human CRC Tissues 
and a Mouse Model of MSI CRC
J Jo oo on ng gh ho o   S Sh hi in n
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K Ke ey y   w wo or rd ds s: :   microsatellite instability, CDK2-AP1,
Mlh1 knockout mouse
B Ba ac ck kg gr ro ou un nd d: :   We have reported (in this forum and
published) that down-regulation of the growth-suppressor
gene, cyclin-dependent kinase 2-associated protein 1
(CDK2-AP1) in microsatellite unstable (MSI) human
colorectal cancer (CRC) cell lines is associated with
increased proliferation and decreased apoptosis in 
those cell lines. In this report we expand our study of
CDK2-AP1 to include a mouse model of MSI CRC as
well as human CRC tissues to validate our cell line based
observations.
M Me et th ho od ds s: :   The DNA mismatch repair (MMR) status of
tumors arising from a knockout mouse, generated 
in our collaborator’s laboratory (Mlh1
–/–/APC
1638N), was
determined by measuring Mlh1 expression by Western
blot and was confirmed by sequencing four mouse
microsatellite markers (D9Mit67, D1Mit79, L24372 and
U12235). CDK2-AP1 expression in the MSI mouse
tumors and adjacent normal mucosa was assessed using
RT-PCR and Western blot analysis. A human CRC tissue
array containing 43 microsatellite stable (MSS) and 7 MSI
CRC tumors was analyzed for CDK2-AP1 expression
using standard immunohistochemistry techniques.
R Re es su ul lt ts s: : All four of the GI tumors harvested from the
Mlh1 knockout mouse exhibited the MSI phenotype and
had significantly decreased levels of CDK2-AP1 mRNA
(p<0.0001) and protein. Normal adjacent mucosa 
from the Mlh1 knockout mouse demonstrated normal
CDK2-AP1 expression. In contrast, tumors harvested from
a control transgenic APC
1638N mouse demonstrated the
MSS phenotype and normal CDK2-AP1 expression as
measured by mRNA and protein analysis. Furthermore,
human CRC tissue array analysis demonstrated 6 of 
7 (85.7%) MSI CRC tumors had significantly decreased
CDK2-AP1 antibody staining, whereas 0 of 43 MSS CRC
tissues demonstrated reduced CDK2-AP1 staining
(p<0.0001).
C Co on nc cl lu us si io on ns s: :   These human tissue and mouse model
results confirm that down-regulation of CDK2-AP1 is
a characteristic of CRC tumors arising from MMR
deficiency. These results provide support for the
hypothesis that MSI and MSS CRCs are characterized
by distinct pathways of malignant transformation and
progression and may provide novel molecular-based
therapeutic opportunities.
[5]
Early Age Onset Adenomatous Colorectal Polyp Formation
Among African Americans is Associated with a Q324H Germline
Sequence Variant of the MutY Homolog (MYH) Gene
Ziqiang Yuan
1, J Jo oo on ng gh ho o   S Sh hi in n
1, Kenneth Fordyce
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1300 Morris Park Avenue, New York, NY 10461; 2Computational Decision Science Group,
IBM USA, Burlington, VT; 3Department of Surgery, University of Pittsburgh Medical Center,
Pittsburgh, PA; 4Salanter Akiva Riverdale High School, New York, NY
K Ke ey y   w wo or rd ds s: : early onset colorectal polyps, MYH
Q324H, African Americans
B Ba ac ck kg gr ro ou un nd d: :   The contribution of germline genomic
variation to increased rates of colorectal cancer (CRC)
incidence among African Americans remains unknown.
Sequence alterations in the MutY human homologue
(MYH) gene have been reported to be associated with
colorectal cancer predisposition in European populations.
This study was designed to test the hypothesis that novel
MYH alterations are associated with colorectal adeno-
matous polyp formation in African Americans.
M Me et th ho od ds s: : One hundred and twenty-three unrelated
African Americans adults with histologically confirmed
multiple or a single large (>1cm) colorectal polyp(s)
were prospectively consented and screened for
germline mutation(s) of the MYH gene by direct
sequencing. Twenty-nine of 123 members of the test
group were ≤50 and 94 were >50 years of age at the
time of polyp diagnosis. A control group of 73 healthy
African American consented volunteers without history
of polyps or CRC were screened for the Q324H variant
using a Bts I restriction endonuclease.
R Re es su ul lt ts s: : Sixty-three (51%) of 123 subjects carried the
germline MYH Q324H alteration, as indicated by direct
sequencing: 50/63 (79%) monoallelic and 13/63 (21%)
biallelic. Among controls 11/73 (15%) carried the
Q324H alteration: 10 (14%) monoallelic and 1 (1%)
biallelic, a statistically significant difference (p<0.01).
Interestingly, in sub-set analysis the Q324H carrier
frequency among subjects diagnosed ≤50 years of age
was 86% (25/29); 17/29 (58%) monoallelic and 8/29
(28%) biallelic and 40/94 (42%) among subjects
diagnosed after 50; 33/94 (35%) monoallelic and 5/94
(5%) biallelic, a statistically significant difference (p<0.05).
C Co on nc cl lu us si io on ns s: : These results indicate the MYH germline
variant Q324 is associated with adenomatous polyp
formation among African Americans especially among
individuals diagnosed at or before age 50. For the futureH He er re ed diit ta ar ry y  C Ca an nc ce er r  iin n  C Clliin niic ca all  P Pr ra ac ct tiic ce e 2007; 5(4) 216
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we plan to expand our studies of the Q324 variant to
include more diverse populations as well as subjects
diagnosed with invasive colorectal cancer.
[6]
Lynch Syndrome Mutation Prevalence in a Large Series of Patients
M Mi ic ch he el ll le e   M Ma ar rt ti in n
1, Lynn A. Burbidge
1, Cynthia Frye
1, Ben Roa,
Richard Wenstrup
1
1Myriad Genetic Laboratories, Inc. 320 Wakara Way, Salt Lake City, UT 84108
K Ke ey y   w wo or rd ds s: : Lynch syndrome, mutation prevalence,
genetic testing
B Ba ac ck kg gr ro ou un nd d: :   Deleterious mutations in the mismatch
repair genes MLH1, MSH2 and MSH6 are known to
cause Lynch syndrome (HNPCC). The aim of this study
was to measure the prevalence of these gene mutations
in groups of patients stratified by personal and family
history as reported on the test requisition form of 
a large commercial laboratory.
M Me et th ho od ds s: :   Myriad Genetic Laboratories offers full
sequencing and Southern blot of MLH1 and MSH2 for
detection of mutations causative of Lynch syndrome.
The more recent addition of MSH6 sequencing has
enhanced this analysis. For the current study, we report
the prevalence of mutations identified in our overall
test population and after stratification by personal and
family history.
R Re es su ul lt ts s: :   Of 6,826 MLH1 and MSH2 gene analyses
performed, 916 (13.4%) patients were identified with
deleterious mutations. Of these patients, 388 had
mutations in the MLH1 gene, representing 42.4% of
all mutation positive patients and 5.7% of the total
tested population. Five hundred twenty-eight (528)
patients were identified with a deleterious mutation in
MSH2, accounting for 57.6% of all mutation positive
patients and 7.7% of the total tested population. MSH6
gene sequencing was performed on a total of 1247
patients; 39 (3.1%) patients had deleterious mutations.
In patients reporting a personal history of colorectal
cancer (CRC) under age 50 and no family history of
Lynch syndrome related cancers, the mutation
prevalence was 7.2% (22/306). Patients with CRC
under 50 who reported a family history of at least one
relative with a Lynch syndrome cancer had a mutation
prevalence in either MLH1 or  MSH2 of 26.5%
(282/1064). Patients reporting a personal history of
more than one Lynch syndrome related cancer and no
family history had a mutation prevalence of 8.8%
(6/68). In patients reporting a personal history of more
than one Lynch syndrome related cancer and a family
history of at least one family member with a Lynch
syndrome related cancer, the mutation prevalence was
43.5% (161/370). Patients with a personal history of
endometrial cancer under the age of 50 who report at
least one family member with a Lynch syndrome cancer,
had a mutation prevalence of 29.6% (45/152). In
patients reporting a personal history of ovarian cancer
regardless of their family history (who may or may not
have relatives with Lynch syndrome related cancers),
we observed a mutation prevalence of 7.4% (16/216).
C Co on nc cl lu us si io on ns s: :   Patients with a personal and/or family
history of Lynch syndrome related cancers are appropriate
candidates for genetic testing of the mismatch repair
genes.
[7]
Colorectal Cancer in Young Patients: Unexpected Clustering 
in the Rectosigmoid Colon, Low Frequency of Classic Lynch
Syndrome,and Involvement of JC virus
Ajay Goel
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1
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Cancer Center; 2Department of Pathology; 3Department of Colorectal Surgery, Baylor
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B Ba ac ck kg gr ro ou un nd d: :   Colorectal cancer (CRC) occurs rarely
in individuals <50 years, and comprises a heterogeneous
group including patients with Lynch syndrome, as well as
those with other non-familial, sporadic cancers. Little is
know about the full spectrum of factors associated with
CRC in young people. This study examined the clinical
features, microsatellite instability (MSI), DNA MMR protein
expression, and JC virus (JCV) expression in patients <50
years old with sporadic, apparently non-familial CRC.
M Me et th ho od ds s: :   Paraffin-embedded tissue sections were
obtained from 82 patients with CRC, all <50 years old,
none of whom came from a familial cluster of CRC.
Immunohistochemical (IHC) staining was performed for
the hMLH1, hMSH2, hMSH6, and hPMS2 proteins, and
for the T-antigen (T-Ag) of JC virus (JCV), an oncogenic
virus found in most sporadic CRCs. MSI analyses 
were performed using a panel of 5 mononucleotide
repeat markers, and used consensus criteria for MSI 
(≥2 mutations=MSI-H).
R Re es su ul lt ts s: :   The mean age of the patient cohort was 
34.4 years (range 16-47 years), and 80/82 were ≤40
years old. Three patients had IBD-associated CRCs, but
none had a polyposis syndrome. Only 26% (22/78 – 4
without clinical information) of the tumors were located
in the proximal colon, while 74% (56/78) were locatedH He er re ed diit ta ar ry y  C Ca an nc ce er r  iin n  C Clliin niic ca all  P Pr ra ac ct tiic ce e 2007; 5(4) 217
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distal to the splenic flexure. Unexpectedly, 41% of the
tumors were in the rectosigmoid or rectum. Overall, 17%
(14/82) of the CRCs were MMR-deficient, based upon
loss of expression of MMR proteins at IHC. Unlike classic
Lynch syndrome, only 43% (6/14) of these MMR-deficient
CRCs (by IHC) demonstrated loss of expression of one
of the two major DNA MMR proteins, hMLH1 or hMSH2
(3 each for hMLH1 and hMSH2), together with the
associated losses of hPMS2 or hMSH6. Of particular
note, 8/14 (57%) of the MMR-deficient CRCs had
experienced the exclusive loss of either hPMS2 (n=3) or
hMSH6 (n=5), without the respective loss of expression
of hMLH1 or hMSH2. While all 9 tumors with hMLH1,
hMSH2, or hPMS2 losses were MSI-H, only 2/5 of the
CRCs with isolated losses of hMSH6 were MSI-H; in both
cases, just 3/5 markers were mutated and in the other
three, none were mutated. In all 3 instances of hPMS2
loss, either 4/5 or 5/5 of the markers were mutated.
Finally, 79% of the CRCs showed strong nuclear staining
for the JCV T-Ag.
C Co on nc cl lu us si io on ns s: : We found that 41% of 82 CRCs in
young patients occurred in the rectosigmoid region. In
this group of non-familial CRCs, 17% had defects in
DNA MMR protein expression, and 57% were atypical,
with isolated losses of hMSH6 or hPMS2. Some (3/5)
of the CRCs with isolated losses of hMSH6 were MSS,
and will be missed by approaches that use MSI to
screen for Lynch syndrome. A small but important
portion (3/82) of these apparently non-familial CRC
patients may have germline mutations in hPMS2, which
could be very important for appropriate genetic
counseling. Finally, the strong expression of JCV T-Ag
in the nuclei of most of these tumors implicates this
oncogenic virus in the genesis of CRC in young people,
including those with DNA MMR defects.
[8]
Long-Term Risk of Pouch Neoplasia After Ileal Pouch Anal
Anastomosis for Familial Adenomatous Polyposis
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K Ke ey y   w wo or rd ds s: : familial adenomatous polyposis, ileal
pouch, neoplasia risk
B Ba ac ck kg gr ro ou un nd d: : Ileal pouch anal anastomosis (IPAA)
is a mainstay of surgical prophylaxis for familial
adenomatous polyposis (FAP), and is thought to virtually
eliminate the risk of cancer. The development of pouch
carcinomas has been reported in isolated cases and 
a number of cross-sectional studies have evaluated the
prevalence of pouch adenomas, but the true long-term
risk and natural history of ileal pouch neoplasia remain
unknown.
M Me et th ho od ds s: :    All available pouch endoscopy and
associated histology reports for patients with FAP attending
for annual surveillance after IPAA at St Mark’s Hospital
since 1978 were reviewed retrospectively. The incidence,
anatomical location and histological characteristics of
pouch neoplasms were recorded. Cumulative adenoma-
free survival was calculated using Kaplan-Meier survival
analysis.
R Re es su ul lt ts s: :   Of 206 patients who underwent IPAA, 140
attended for endoscopic follow-up at this institution. The
median adenoma-free survival in the pre-pouch ileum
(PPI), pouch body, and anal transitional zone (ATZ) was
10.1, 7.2 and 8.1 years respectively, with 83%, 18% and
41% of patients remaining adenoma-free at 20 years.
Adenomas were mildly dysplastic in 88% of PPI, 81% of
pouch and 71% of ATZ polyps, with the remainder being
predominantly moderately dysplastic. The maximum size
of adenoma recorded was 4 mm in the PPI, 40 mm in
the pouch and 60 mm in ATZ. There were no instances
of progression in the PPI. In the pouch body, 2 patients
developed large villous adenomas (>5 mm), and 8 had
tubulovillous adenomas, 3 of which were large. In the
ATZ, 4 patients developed large tubulovillous adenomas,
and one had adenocarcinoma after 19 years. In total, 
4 patients required pouch excision for neoplasia.
C Co on nc cl lu us si io on ns s: :   The majority of FAP patients develop
benign neoplasms in the pouch body and ATZ in the
long term. Although malignant transformation is rare,
regular endoscopic surveillance is mandatory and
further research is required to identify risk factors for
pouch malignancy in the long term.
F Fu un nd di in ng g: : Alexander von Roon is supported by a Royal
College of Surgeons of England Research Fellowship.
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Educational Outreach to Individuals at Risk for Hereditary Colon Cancer
J Ja an n   T T. .   L Lo ow we er ry y, Lisen Axell, Wendy Garlitz
University of Colorado and Denver Health Sciences Center, Cancer Center, UCDHSC 
at Fitzsimons, 13001 E. 17
thPl., Aurora, CO 80045
K Ke ey y   w wo or rd ds s: :   HNPCC, educational outreach, cancer
registry
B Ba ac ck kg gr ro ou un nd d: :   Colorectal cancer (CRC) accounts for
over 150,000 new cancer cases and 52,000 deaths
each year in the U.S. About 3% of CRC is attributed toH He er re ed diit ta ar ry y  C Ca an nc ce er r  iin n  C Clliin niic ca all  P Pr ra ac ct tiic ce e 2007; 5(4) 218
Lynch syndrome, also called hereditary non-polyposis
colon cancer. Individuals with Lynch syndrome have
significant lifetime risk of developing CRC, upwards of
80%, as well as risk for other related cancers. Thus,
identifying these individuals is important for reducing
morbidity and mortality from associated cancers. Genetic
counseling and testing for Lynch syndrome are under-
utilized in Colorado. The purpose of this project was to
educate Coloradans at risk for hereditary CRC about the
benefits of cancer risk assessment and to provide
assessment via telephone to individuals without access
to this service. A secondary aim was to determine the
feasibility of utilizing a cancer registry for identifying 
at-risk individuals and conducting educational outreach.
M Me et th ho od ds s: :   At-risk individuals were identified through
the Colorado Central Cancer Registry. Cases were
recently diagnosed with CRC who met one of the first
three criteria of the revised Bethesda criteria. The
physician of record was mailed an educational
brochure about hereditary CRC, a brief survey and
asked to provide consent to contact their patient(s).
Cases were mailed the brochure and a one-page
survey to elicit reactions to being contacted via the
registry. Follow-up surveys were mailed to cases about
4 months after the initial mailing.
R Re es su ul lt ts s: : In total, 575 cases and 412 physicians were
identified by the registry. About 40% of physicians (169)
representing 226 patients provided consent to contact
patients. Among physicians who completed the survey,
the majority felt the educational information was clearly
presented and useful. Most (77%) reported they
currently discuss cancer genetics with their patients and
90% felt the registry should provide this information to
at-risk patients, with (30%) or without (60%) physician
consent. Forty-three of the 181 cases contacted
completed the initial survey (23%). Cases were generally
glad to have received the information and wanted to
know more. Only 4 cases reported concern or worry in
response to the information. The majority of cases
agreed the registry should send this information;
however most preferred that their physicians be
consented first. At follow-up, 20 cases reported having
had risk assessment in the past 4 months or had
intentions to have risk assessment, and about 45%
reported having discussed risk assessment with
someone. No cases called the toll-free line for genetic
information; thus no referrals were made.
C Co on nc cl lu us si io on ns s: :   The response from physicians and cases
regarding both the content of the materials and the mode
of delivery was positive, suggesting that targeted outreach
using the cancer registry, in combination with physician
notification, may be a viable approach to disseminating
genetic information. A sizeable proportion of cases either
sought risk assessment or discussed it with others,
suggesting that mail-based outreach may be effective in
increasing uptake of information and/or genetic services.
The lack of calls to the information line may reflect
patients’ preference to confer first with providers and/or
persons of trust regarding these issues. Uptake for
telephone risk assessment may be improved after
establishing clinical relationships with patients.
F Fu un nd di in ng g: :   This project was funded by the Mountain
States Genetics Collaborative.
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The Revised Bethesda Guidelines: Extent of Utilization in a University
Hospital Medical Center with a Cancer Genetics Program
Aparna Mukherjee, M Ma ar ri ia a   J J. .   B Ba ak ke er r, Walter Koltun, 
Kevin McKenna, Lisa Poritz, Thomas McGarrity
Penn State Hershey Medical Center, 500 University Drive, Hershey, PA 17033-0850
K Ke ey y   w wo or rd ds s: : revised Bethesda guidelines, HNPCC,
microsatellite instability
B Ba ac ck kg gr ro ou un nd d: :   In 1996, the National Cancer Institute
hosted an international workshop to define a set of
clinicopathologic criteria to help identify patients with
colorectal cancer who should be offered microsatellite
instability (MSI) testing due to an increased risk for
hereditary nonpolyposis colorectal cancer (HNPCC).
These criteria were further modified in 2004 and became
known as the revised Bethesda guidelines. In our quality
assurance study, we aimed to retrospectively evaluate,
over the course of one year, the percentage of patients
diagnosed and treated for HNPCC-associated tumors
who met revised Bethesda criteria, making them eligible
for MSI testing, who were referred for genetic counseling
services within our institution. This retrospective study
identified a number of barriers, both internal and external,
which hindered the identification of individuals with
HNPCC, thus limiting the ability to appropriately manage
these high risk families.
M Me et th ho od ds s: :   All HNPCC-associated tumors diagnosed
between January 1, 2004 and December 31, 2004 were
identified by accessing CoPath, an internal database.
Both the Tumor Registry and patients’ electronic medical
records were then accessed to gather all relevant family
history information. The revised Bethesda criteria were
applied to each case to ascertain which patients fulfilled
at least one criterion that would warrant MSI testing. This
list was then cross-referenced with the database of
patients referred for genetic counseling within our
institution.
R Re es su ul lt ts s: : A total of 380 HNPCC-associated tumors
were diagnosed at our institution between January 1 and
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December 31, 2004 of which 41 (10.7%) met at least
one of the revised Bethesda criteria. Eight (19.5%) of
these patients were referred for cancer genetic counseling
of which 2 (25%) were seen by a genetics professional.
Ultimately, only 4.9% of eligible patients who met revised
Bethesda criteria for MSI testing in 2004 at our institution
were seen for genetic counseling. Of importance, it was
not possible to determine for 145 HNPCC-associated
tumors (38%) whether their personal and family history
met at least one of the revised Bethesda criteria.
C Co on nc cl lu us si io on ns s: :   Our study highlights several barriers,
both within and external to our institution, regarding the
application of the revised Bethesda criteria to identify 
at-risk patients with HNPCC-related tumors. These barriers
include the lack of detailed family histories captured by
health care providers and the failure of pathologists to
routinely characterize MSI-H histology in colorectal cancer
specimens. Patient compliance represents another barrier
identified in part due to limited knowledge regarding the
potential benefits of genetic screening and testing for
HNPCC, reservations regarding the sensitive nature 
of information gleaned from genetic testing, and
insurance coverage issues due to the lack of recognition
of board certified masters and doctoral trained genetics
professionals by major insurers.
[11]
The Impact of Genetic Counseling for Attenuated Familial
Adenomatous Polyposis
W We en nd dy y   K K. .   K Ko oh hl lm ma an nn n, Angela Schwab, Jennifer Lilley, 
Kory W. Jasperson, Lisa M. Pappas, Anita Y. Kinney, 
Randall W. Burt
University of Utah Huntsman Cancer Institute, 2000 Circle of Hope Dr., Salt Lake City, 
UT 84112-5550
K Ke ey y    w wo or rd ds s: :    attenuated familial adenomatous
polyposis, genetic counseling, risk perception
B Ba ac ck kg gr ro ou un nd d: :    Families with attenuated familial
adenomatous polyposis (AFAP) lack the dramatic
presentation of hundreds of colon polyps which brings
families with classic polyposis to medical attention. The
minimal polyp burden, later age of onset, and fewer
relatives with cancer may prohibit recognition of a genetic
syndrome by clinicians and lead to underestimation of
risk by family members. Therefore families with AFAP may
have unique genetic counseling needs. In this study we
evaluated the impact of genetic counseling on distress,
cancer worry, risk perception, and knowledge in members
of a large AFAP kindred previously described by Burt 
et al. in 2005.
M Me et th ho od ds s: : Members of an AFAP kindred who were
at 50% risk for having inherited a familial APC mutation
were offered the opportunity for free genetic counseling
and testing. Standardized measures including the
Center for Epidemiologic Studies Depression Scale and
Impact of Events Scale, along with true/false, cancer
worry and risk perception questions developed based
on previously validated tools were used. Differences
between pre- and post-counseling were assessed using
the Wilcoxon signed rank test.
R Re es su ul lt ts s: :   Forty-four of 99 subjects enrolled in the
genetic testing study completed pre- and post-counseling
written questionnaires. Eighty percent of participants
reported education past high school. Following genetic
counseling, participants were found to have significantly
lower levels of depressive symptoms (p≤0.0001). Twenty-
four percent had an increase in cancer specific worry, but
over the entire group of participants the change was not
significantly different pre- and post-counseling (p=0.4).
Prior to genetic counseling, participants underestimated
their risk of having a genetic mutation. After counseling
42% increased their risk estimate, resulting in an accurate
mean of approximately 50% (p=0.0065). Improvements
in knowledge were also observed (p=0.058).
C Co on nc cl lu us si io on ns s: : These data are from a well studied
family in which members were notified that there was 
a known genetic mutation prior to enrolling. Despite this,
most individuals underestimated their risk prior to
counseling. It is likely that other AFAP families that have
not experienced intensive outreach interventions may be
less aware of their risks. Genetic counseling may be an
effective approach for improving the accuracy of risk
perception and knowledge about hereditary cancer. These
data also suggest that through the genetic counseling
process, individuals can be informed of their cancer and
genetic risks without inducing increased distress or
depression. However, in order for individuals at risk for
AFAP to access genetic services, further education is
needed to ensure that clinicians are appropriately
identifying and referring these families.
[12]
The Frequency of the Revised Bethesda Guidelines 
and Additional Criteria in a Large Population Database
K Ko or ry y   W W. .   J Ja as sp pe er rs so on n, Jared Cox, Deborah W. Neklason, 
Randall W. Burt
University of Utah Huntsman Cancer Institute, 2000 Circle of Hope Dr., Salt Lake City, 
UT 84112-5550
K Ke ey y   w wo or rd ds s: : Lynch syndrome, revised Bethesda
guidelines, endometrial cancerH He er re ed diit ta ar ry y  C Ca an nc ce er r  iin n  C Clliin niic ca all  P Pr ra ac ct tiic ce e 2007; 5(4) 220
B Ba ac ck kg gr ro ou un nd d: :   The revised Bethesda guidelines (BG)
were developed to identify individuals who are
appropriate candidates for tumor testing using
microsatellite instability (MSI) analysis. Except for criterion
II, the BG currently require a diagnosis of colorectal
cancer (CRC) in individuals being evaluated for Lynch
syndrome. It has also been suggested that individuals
with endometrial cancer meeting certain criteria be
included in the BG due to the high lifetime risk associated
with Lynch syndrome. Here we determine the prevalence
of individuals in a large population database who meet
the BG using both colorectal and endometrial cancer 
as the indication for evaluation.
M Me et th ho od ds s: : Using the Utah Population Database
(UPDB), which links Utah family histories to Utah cancer
records, we determined the number of individuals that
met BG I, II, IV or V. BG III was not evaluated due to
lack of available records necessary to determine this
criterion. Individuals meeting BG II are not required to
have a diagnosis of colorectal or endometrial cancer,
as any two Lynch syndrome-associated tumors meet
the criteria. We also evaluated the frequency of BG I,
IV, and V using endometrial cancer as the indication
for testing.
R Re es su ul lt ts s: :   Of the 25,806 CRCs in the UPDB, 2346
(9.1%) met BG I, 675 (2.6%) met BG IV, and 1,781
(6.9%) met BG V. There were 7754 endometrial
cancers in the UPDB and when these cancers were
included in the evaluation, 3670 (10.9%) individuals
met BG I, 1,054 (3.1%) met BG IV, and 3,226 (9.6%)
met BG V. Of the 49,038 total cases of Lynch
syndrome-associated tumors in the UPDB, 1480 (3%)
met BG II. There were 5,483 individuals that met at
least one BG, and an additional 2,679 individuals met
criteria when endometrial cancer was included.
C Co on nc cl lu us si io on ns s: :   The UPDB provides a unique resource
to evaluate the frequency of probands meeting current
and proposed guidelines for evaluation of Lynch
syndrome. Including both endometrial and colorectal
cancer as indications for testing resulted in 8,162
individuals meeting criteria, compared to 5,483 cases
when endometrial cancer was not included in BG I, 
IV or V.
[13]
BRAFMutations in Hereditary Non-Polyposis Colorectal Cancer
and Bethesda Criteria Patients: a Pilot Study
Francesca Molinari
1, Federica Perrone
2, Andrea Lampis
2, 
Paola Sala
3, Chiara Bassi
4, Michele Sardella
4, Paolo Radice
5,
Marco A. Pierotti
5, Milo Frattini
1, Silvana Pilotti
2, L Lu uc ci io o   B Be er rt ta ar ri io o
3
1Laboratory of Molecular Diagnostic, Institute of Pathology, Locarno, Switzerland; 2Unit 
of Experimental Molecular Pathology, Department of Pathology; 3Preventive-Predictive Medicine
Unit; 4Department of Experimental Oncology, Istituto Nazionale per lo Studio e la Cura dei
Tumori, Milan, Italy; 5Department of Experimental Oncology, Istituto Nazionale per lo Studio
e la Cura dei Tumori and FIRC Institute of Molecular Oncology (IFOM), Milan, Italy
K Ke ey y   w wo or rd ds s: : BRAF, microsatellite instability, Bethesda
criteria
B Ba ac ck kg gr ro ou un nd d: : Hereditary non-polyposis colorectal
cancer (HNPCC) syndrome is clinically defined by the
Amsterdam criteria. However, some patients do not match
these criteria exactly and therefore are classified as
suspected HNPCC, according to Bethesda guidelines.
At a molecular level, HNPCC patients are characterized
by “germ-line” mutations in mismatch repair (MMR) genes
leading to microsatellite instability (MSI). MMR genes can
be altered at a somatic level also in up to 15% of
sporadic colorectal cancers (CRC).
Interestingly, BRAF mutations occur more frequently
in MSI than in microsatellite stable (MSS) sporadic CRCs
and particularly segregate with MLH1 promoter
hypermethylation. Notably, no BRAF mutations have been
identified in HNPCC patients with known germ-line MMR
gene mutation. However, little is known about BRAF status
in suspected-HNPCC patients, who, by definition, have
a high risk of carrying mutations in MMR genes. Since
BRAF mutation and HNPCC are mutually exclusive, our
aim was to verify whether the presence of BRAF mutation
may help clinicians in the identification of suspected
HNPCC patients with MSI profile avoiding the assessment
of germ-line MMR mutation.
M Me et th ho od ds s: :    We selected 120 CRCs (Register of
Hereditary Colorectal Tumours) including 27 HNPCC
patients fulfilling Amsterdam criteria and carrying germ-
line MMR gene mutation, 37 suspected HNPCC patients
T Ta ab bl le e   1 1. .   Revised Bethesda guidelines (Umar et al. 2004) 
Requires at least one of the following in an individual being 
evaluated:
(I) Colorectal cancer diagnosed prior to age 50
(II) Presence of two primary Lynch syndrome-associated tumors*
(III) Colorectal cancer diagnosed less than 60 years of age 
with MSI-high histology
(IV) Colorectal cancer and one or more first degree relatives 
with a Lynch syndrome-associated tumor*, with at least one 
of the cancers being diagnosed under age 50 years
(V) Colorectal cancer and two or more first or second degree 
relatives with a Lynch syndrome-associated tumor*, 
regardless of age
*colorectal, endometrial, stomach, ovarian, pancreas, sebaceous gland, ureter,
renal pelvis, and biliary tract cancer, keratocanthoma, glioblastoma, 
and carcinoma of the small bowel
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according to Bethesda guidelines and 56 sporadic
patients. Microsatellite status and BRAF mutations were
investigated according to standard procedures already
published.
R Re es su ul lt ts s: : MSI was found in 40 out of 64 (62.5%)
HNPCC and suspected-HNPCC cases. No BRAF
mutations were found in 27 HNPCC patients. In the
suspected HNPCC patient group, only 2 out of 37 (5%)
tumours showed BRAF mutations, including the classical
V600E in a MSI case and the not frequent, but already
reported, N580S change in a MSS case. As comparison,
MSI was found in 10 out of 56 (18%) sporadic cases and
the classical BRAF V600E mutation was detected in 
2 out of 10 (20%) MSI and in 1 out of 46 (2%) MSS
sporadic cases.
C Co on nc cl lu us si io on ns s: :   BRAF mutations are associated with MSI
sporadic CRCs, and absent in HNPCC patients, thus
confirming previous reports. Moreover, BRAF is rarely
mutated in suspected HNPCC patients (Bethesda
guidelines). Therefore, in suspected HNPCC the BRAF
mutation testing seems to have a modest impact on the
exclusion of patients from the characterization of germ-
line MMR gene mutations.
[14]
Rapid Activation of Hereditary Colorectal Cancer Counseling Program
D De eb bo or ra ah h   N Na ag gl le e, Jeff Goldsmith, Doug Pleskow, Taryn Schiripo,
Jill Krejdovsky
Beth Israel Deaconess Medical Center, 330 Brookline Avenue, Boston, MA 02215
B Ba ac ck kg gr ro ou un nd d: :   Beth Israel Deaconess Medical Center
(BIDMC) has an established Genetics and Cancer
Prevention Program that had low level activity in the
area of hereditary colon and rectal cancer.
M Me et th ho od ds s: : We formed a small working group of
physicians (gastroenterology, colorectal surgery,
pathology and medical oncology), genetic counselors
and hospital administrators to create a Hereditary
Colorectal Cancer Program (HCRCP) with defined
management pathways for patients and family members
at risk for, or diagnosed with, inherited colorectal
cancer. We added a second gastroenterologist (January
2007). We added reflex microsatellite instability testing
(msi) for all colon cancer specimens in patients age 50
and under in our institution. We upgraded and updated
our computerized data collection system (Progeny). We
prospectively tracked referrals to the Program and
compared them to historical volumes.
R Re es su ul lt ts s: :   Our program-building work was initiated at
the beginning of fiscal year 2007 (October 2006) with
an immediate increase in referral volume (Table 1).
Reasons for referral included: patients with colon cancer,
family history of colon cancer, family history of hereditary
non-polyposis cancer (HNPCC) and polyps. There was
an increase in rate of referral for family cancer syndromes
and polyps compared to historical volumes. We saw 
a significant increase in referrals from gastroenterology,
medicine and hematology-oncology.
T Ta ab bl le e   1 1. .   Referrals to BIDMC-HCRCP by fiscal year
F FY Y Q Q1 1- -2 2 Q Q3 3- -4 4
FY 04 4 7
FY 05 3 4
FY 06 0 0
FY 07* 16 30 (annualized)
*15 thru June 2007
C Co on nc cl lu us si io on ns s: :   With a small group organizational
effort to create basic structure, but without formal
program promotion, we significantly increased referrals
to and utilization of our Hereditary Colon and Rectal
Cancer Program. In particular, medical specialities
demonstrated increased knowledge and awareness of
hereditary cancer syndromes via their referrals. Next
steps at our institution include program promotion and
research initiatives.
[15]
Cyclooxygenase-2 and Platelet-Derived Growth Factor Receptors 
as Potential Targets in Treating Aggressive Fibromatosis
Elisa Pastore
1, Milo Frattini
1-3, Stefano Signoroni
1,2, Tiziana
Negri
1, Elena Tamborini
1, Paola Casieri
1, Marta Orsenigo
1, 
Luca Da Riva
1, Paolo Radice
2, Paola Sala
4, Alessandro Gronchi
5,
Silvana Pilotti
1, Marco A. Pierotti
2,4-6, L Lu uc ci io o   B Be er rt ta ar ri io o
4
1Experimental Molecular Pathology, Department of Pathology; 2Department of Experimental
Oncology, Fondazione IRCSS Istituto Nazionale dei Tumori, Milan, Italy; 3Laboratory 
of Molecular Diagnostic, Institute of Pathology, Locarno, Switzerland; 4Preventive-Predictive
Medicine Unit; 5Department of Medical Oncology, Fondazione IRCSS Istituto Nazionale
dei Tumori, Milan, Italy; 6IFOM, FIRC Institute of Molecular Oncology, Milan, Italy
K Ke ey y   w wo or rd ds s: : aggressive fibromatosis, RTK activation
profile, COX-2, PDGFRA, PDGFRB
B Ba ac ck kg gr ro ou un nd d: :   To explore the molecular bases of
potential new pharmacological targets in aggressive
fibromatosis (AF) (desmoid tumour).H He er re ed diit ta ar ry y  C Ca an nc ce er r  iin n  C Clliin niic ca all  P Pr ra ac ct tiic ce e 2007; 5(4) 222
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M Me et th ho od ds s: : Tumour specimens from 14 patients surgi-
cally treated for AF, 6 familial adenomatous polyposis
(FAP) and 8 sporadic cases, analyzed for APC and
CTNNB1 (β-catenin) mutations were further investigated
for β-catenin, COX-2, PDGFRA/PDGFRB, their cognate
ligands (PDGFA and PDGFB) and KIT using a compre-
hensive immunohistochemical, biochemical, molecular
and cytogenetic approach.
R Re es su ul lt ts s: :   No CTNNB1 (β-catenin) mutations were
found in the FAP patients, but previously reported
activating mutations were found in 6 of the 8 sporadic
patients. All of the cases carrying an altered WNT
pathway showed nuclear and cytoplasmic immuno-
reactivity for β-catenin, whereas β-catenin expression was
restricted to the cytoplasm in the sporadic patients lacking
CTNNB1 mutations. COX-2 protein and mRNA
overexpression was detected in all 14 cases, together with
the expression and phosphorylation of PDGFRA and
PDGFRB, which in turn paralleled the presence of their
cognate ligands. No PDGFRB mutations were found. The
results are consistent with PDGFRA and PDGFRB
activation sustained by an autocrine/paracrine loop.
C Co on nc cl lu us si io on ns s: :   AF is characterized by WNT-oncogene
pathway alterations triggering COX-2-mediated consti-
tutive co-activation of PDGFRA and PDGFRB and may
benefit from combined non-steroidal anti-inflammatory
drugs (NSAIDs) + tyrosine kinase inhibitor treatment.
[16]
Long-Term Follow up of Subjects to Assess Changes in the Family
History of Colorectal Cancer and to Identify New Family History
Risks and New Hereditary Colorectal Cancer Syndromes
K Kw we ek ku u   A Ap pp pa au u, Carol A. Burke, Mathew Kalady, 
Ellen McGannon, Susan Fay, James Church
Departments of Colorectal Surgery; Gastroenterology and Cancer Center, The Cleveland
Clinic Foundation, Cleveland, OH
K Ke ey y    w wo or rd ds s: : family history, colorectal cancer,
surveillance recommendations
B Ba ac ck kg gr ro ou un nd d: : Family history of colorectal cancer is
an important risk factor for the disease. The strength
of family history determines the intensity of colorectal
cancer screening or surveillance. Few studies have
investigated changes in familial risk for colorectal
cancer and the impact of the change on the frequency
of screening or surveillance recommendations.
To determine if a family history of colorectal neoplasia
changes after 10 years and whether the change affects
screening or surveillance recommendations.
M Me et th ho od ds s: :   The study cohort was incepted in 1991
during a family history-based, public colorectal cancer
screening program. The program offered a free risk
assessment to callers and free flexible sigmoidoscopy to
individuals with one first or second degree relative with
colorectal cancer. 1440 people participated in the risk
assessment and they were categorized into three groups.
Group 0 (no family history), Group I (one first or second
degree relative affected with colorectal cancer), and Group
II (more than one first or second degree relative affected).
In 2001, responders were contacted by phone to update
their family history of colorectal neoplasia. Those not
contactable by phone were sent a questionnaire.
R Re es su ul lt ts s: :   Responses were obtained from 30% in
Group 0 (122/407), 39% in Group I (132/336), and
15% in Group II (104/697) (Table 1).
C Co on nc cl lu us si io on ns s: :   Family history of colorectal cancer
increased over 10 years in 26% of families. The change
appeared to be stronger in originally weak family histories.
These changes resulted in a reassignment of risk and
change in screening or surveillance recommendations in
58% (54/93) of families, as well as identified new families
with hereditary colorectal cancer syndromes. These data
underscore the crucial necessity of updating family history
of colorectal cancer in order to provide screening or
surveillance recommendations that reflect current risk of
the disease.
T Ta ab bl le e   1 1. .   Change in family history of CRC and screening/surveillance recommendations over 10 years
G Gr ro ou up p N N   r re es sp po on nd de er rs s    N N   ( (% %) )   w wi it th h    % %   F FH Hx x   c ch ha an ng ge e N N   w wi it th h   n ne ew w   H HN NP PC CC C N N   w wi it th h   c ch ha an ng ge e    N N   w wi it th h   n no o   c ch ha an ng ge e   
i in n   2 20 00 01 1 n ne ew w   F FH Hx x    b ba as se ed d   o on n   C CR RC C b ba as se ed d   o on n   A AM M- -I I    i in n   S Sc cr r/ /S Su ur r   R Re ec cs s i in n   S Sc cr r/ /S Su ur r   R Re ec cs s
0 122 33 (27%) 45% 0 22 11
I 132 40 (30%) 48% 1 30 10
II 104 20 (19%) 31% 2 2 18
Total 358 93  (26%) 42% 3 54 39
N – number of participants; FHx – family history; CRC – colorectal cancer; AM-I – Amsterdam I Criteria for Hereditary Nonpolyposis Colorectal Cancer; 
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HNPCC and Endometrioid Cancer: Case Report and Review 
of the Literature
J Ja ai im me e   L L. .   B Bo oh hl l, Duveen Sturgeon, Gautam G. Rao, Paul E. Wise
Divisions of General Surgery and Gynecologic Oncology, Vanderbilt University Medical
Center, D5248 Medical Center North, Nashville, TN 37232-2543; (615) 343-4612
K Ke ey y   w wo or rd ds s: :   endometrioid cancer, endometriosis
associated intestinal tumors, HNPCC
B Ba ac ck kg gr ro ou un nd d: :   Hereditary nonpolyposis colorectal
cancer (HNPCC) is a disorder of DNA mismatch repair
that has autosomal dominant inheritance and leads to
increased risk for colon and endometrial cancer, amongst
others. Independent of HNPCC, endometrioid cancer
has been reported to arise in foci of endometriosis with
endometriosis-associated intestinal tumor (EAIT) being 
a rare variant.
M Me et th ho od ds s: :    We report an HNPCC patient with
endometrioid cancer despite a hysterectomy twelve
years earlier. We also present a review of the English
literature through a Medline search from 1970-2007
of endometrioid cancer in HNPCC and EAIT.
R Re es su ul lt ts s: :   An otherwise healthy 54-year-old female
(family history fulfilled Amsterdam II criteria for HNPCC)
status post hysterectomy and bilateral oopherectomy for
endometriosis (age 42) and status post right colectomy
for a stage I colon cancer (age 49) presented with
complaints of pelvic pain. A 1.5 cm mass was found on
CT between the rectum and vaginal cuff. Colonoscopy
was normal. She underwent a margin negative, low
anterior resection with en bloc resection of the pelvic
mass and vaginal cuff. Pathology showed a serous
adenocarcinoma arising from a focus of endometriosis
with transmural involvement of the colon. One of twelve
lymph nodes was positive for cancer and she underwent
adjuvant chemotherapy with carboplatin and taxol. She
presented within months with tumor seeding of the
wound, and repeat CT scan showed a recurrence of her
pelvic mass. External beam radiation to the wound 
and pelvis, followed by repeat surgical excision
(abdominoperineal resection) with negative margins,
failed to prevent recurrence. Nineteen months after her
original presentation, the patient entered hospice after
failing further salvage chemotherapy. Microsatellite
instability (MSI) and immunohistochemistry testing of her
colon cancer showed it to be MSI-high with a loss of
MSH2. Mutational analysis is pending. Literature review
shows 19 cases of EAIT within the rectosigmoid colon.
There are no reported cases of endometrioid cancer
associated with HNPCC. Hyper-estrogenism is an
identified risk factor for endometrioid cancer.
Endometrioid cancer is usually low grade and confined
to its site of origin, so complete surgical excision is
recommended. There is an 82% overall five year survival
rate with survival for disseminated disease being only
12.5% at five years. Chemotherapy is of unclear benefit.
C Co on nc cl lu us si io on ns s: : Endometrioid cancer is rare and not
previously reported in HNPCC. This malignancy must
be considered in patients with HNPCC and a history of
endometriosis despite previous hysterectomy. Outcomes
of disseminated endometrioid cancers and EAIT are poor
and require an aggressive multidisciplinary approach.
[18]
Fate or Family: Do African American Men Have a Higher Risk 
of Colorectal Cancer Due to Family History?
L Li is sa a   L La aG Gu ua ar rd di ia a, Margaret O’Malley, Kathleen Toderick, 
Elena Manilich, James Church
David G. Jagelman Registries, Department of Colorectal Surgery, Cleveland Clinic Foundation
B Ba ac ck kg gr ro ou un nd d: :   Colorectal cancer is the third most
common cancer found in men and women in the
United States. Over the past 15 years the death rate
from colorectal cancer has decreased due to fewer
cases as a reflection of improved colorectal cancer
screening. African Americans have the highest number
of colorectal cancer cases and the highest death rates
from colorectal cancer of all racial groups in the
United States. The reason for this is not yet known and
should be explored.
M Me et th ho od ds s: :   Participants were recruited at a minority
health fair where African American men were asked to
complete a validated family history scoring system which
was previously published by our group. The program was
designed where family history was entered by answering
a series of questions, including the relationships of
affected relatives to the person being screened, and their
age at diagnosis. The program calculated the Family
History Score. No identifying information was collected.
Recommendations for surveillance were given depending
on the risk level assigned. Patients who score 0 are of
average risk and are not significantly different than the
average population. Patients with scores <7 are
considered at low familial risk of cancers or advanced
adenomas while scores >8 signify high risk. Scores >11
are suggestive of a hereditary colorectal cancer syndrome.
This study was approved by the Institutional Review Board
at the Cleveland Clinic.
R Re es su ul lt ts s: :   157 African American men participated.
The scores are shown in the Table 1.H He er re ed diit ta ar ry y  C Ca an nc ce er r  iin n  C Clliin niic ca all  P Pr ra ac ct tiic ce e 2007; 5(4) 224
T Ta ab bl le e   1 1. .
S Sc co or re e R Ri is sk k   l le ev ve el l N N
0 average population 130 (83%)
1-7 low increased 23 (15%)
8-10 high increased 3 (2%)
>10 likely HNPCC 1 (1%)
18% of African American men had an increased
risk of colorectal cancer based on family history. One
patient with likely HNPCC had a score of 15.
C Co on nc cl lu us si io on ns s: :   Using the Family History Scoring
System, African American men are at a significantly
higher risk of colorectal cancer due to family history.
These findings suggest that family history may be one
of the contributing factors for an increased morbidity
rate in African Americans. A comprehensive pedigree
should be taken when interviewing minorities during
patient visits in an effort to educate those at risk and
provide appropriate screening.
[19]
Recruitment of Large Colorectal Cancer Families Through 
a Population-Based Cancer Registry
M M. .S S. .   L Le ew wa an nd do ow ws sk ki i, D.W. Neklason, K.W. Jasperson, 
A.Y. Kinney, R.W. Burt
Huntsman Cancer Institute, University of Utah, 2000 Circle of Hope, Salt Lake City, 
UT 84112-5550
K Ke ey y   w wo or rd ds s: : family expansion, recruitment, population-
based cancer registry
B Ba ac ck kg gr ro ou un nd d: :   This study demonstrates the feasibility
of using a statewide cancer registry to contact cancer
probands and expand the family for clinical and
genetic study. The objective was to identify large high-
risk colorectal cancer (CRC) families from the Utah
Population Database (UPDB) and to expand and recruit
these large families from CRC probands contacted
through the Utah Cancer Registry (UCR). UPDB is 
a genealogic resource containing over 5 million
individual records of people who had a significant life
event (birth, death, childbirth) in Utah or who are
ancestral to current members of the Utah population.
UPDB is also linked to the state-wide UCR.
M Me et th ho od ds s: : Families for study were selected from
UPDB as having a significant p-value for familial
aggregation of CRC (p<0.05) and an increased
familial standardized incidence ratio (FSIR, ratio of
observed to expected) for CRC. CRC cases in the
families were contacted by UCR through a letter asking
them, or their next-of-kin (NOK), permission to be
contacted by the study. The study then contacted
interested individuals and expanded the kindred
through family referral. Referrals were made both
verbally and through a written family contact form.
R Re es su ul lt ts s: : UCR sent letters to 404 CRC cases diagnosed
from 1966 to 2003 for referral to research. Contact was
made on 261 cases (65%) by contacting the probands
(n=210) or their NOK (n=51); the remaining 143 cases
were unavailable. Consent was obtained on 76% 
(198 cases) of those contacted. The NOK were more
likely to consent (94%) vs. the probands (72%). We report
on family expansion from UCR contact (n=32) obtained
for six large kindreds (of 78 requests submitted, 
9 declined contact or were unavailable and 37 are still
pending). The average number of CRC cases per family
was 11.3 (median=11; range=4 to 17). In total, the
study contacted 8 cases and 14 NOK from the six
kindreds. To date, 1 case and 4 NOK failed to result in
family expansion, whereas 7 cases and 10 NOK resulted
in 78 and 68 family members enrolled, respectively. Ten
cases/NOK have not yet been contacted. Recruitment
for three families is now complete and the numbers of
participants (n=44, n=40, and n=24) is sufficiently large
for genetic analysis.
C Co on nc cl lu us si io on ns s: : We report implementation of 
a successful model for recruitment from individual CRC
cases contacted through a statewide cancer registry.
Although UPDB is a unique resource, this model can
be generally applied to smaller families expanded from
individual cancer cases identified through other
population-based cancer registries. Of those cases
and NOK successfully contacted by UCR, the majority
provided consent to be contacted by the study and
referral to their family members for expansion.
[20]
Darwin Meets Familial Adenomatous Polyposis: the Evolution 
of Prophylactic Surgery in Response to Two Major Developments 
in Technique
A An nd dr re e   d da a   L Lu uz z   M Mo or re ei ir ra a, James M. Church
Department of Colorectal Surgery, Cleveland Clinic, Ohio
K Ke ey y    w wo or rd ds s: : familial adenomatous polyposis,
laparoscopy, ileo-pouch anal anastomosis
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B Ba ac ck kg gr ro ou un nd d: : Colectomy with ileo-rectal anastomosis
(IRA) for familial adenomatous polyposis (FAP) was the
standard from 1919 until the development of the ileo-
pouch anal anastomosis (IPAA). Ten years later,
laparoscopic colectomy began. The aim of this study was
to review all the index surgeries for FAP performed at our
institution assessing the effect of changes in surgical
techniques.
M Me et th ho od ds s: : All index FAP surgeries performed at this
institution were reviewed. The procedures were stratified
by date using 1983 (first IPAA) and 1992 (first laparoscopic
colectomy).
R Re es su ul lt ts s: : 395 patients were included; 51.8% were
men. Follow-up ranged from 1 to 540 months, (median
48 months). Before 1983, 97% (66/68) of surgeries were
IRA. The rate of a completion proctectomy was 46%
(31/66). After 1983 60% of surgeries were IRA and 38%
were IPAA. 69% with severe phenotype (>1000 polyps)
had IPAA. Between 1992 and 2006, 39% (70 IRA/17
IPAA) of the surgeries were laparoscopic, with 4.6%
(4/87) conversion rate. From 126 IPAA surgeries, 32%
(40/126) were one-stage and mucosectomy was
performed in 23% (29/126). In those patients who had
surgery and a genetic test, the mutation was below codon
1068 in 85% (29/34) of the IRA group and above codon
1287 in 86% (6/7) of the IPAA group.
C Co on nc cl lu us si io on ns s: :   Colon surgery for FAP has evolved as
advances in surgical technique allow more effective
polyp control while preserving quality of life. Current
strategy uses polyposis severity to decide which surgery
and laparoscopy to minimize morbidity.
[21]
Prospective Analysis of Computed Tomographic Colonography 
in the Evaluation of Familial Adenomatous Polyposis
M Ma ar rg ga ar re et t   O O’ ’M Ma al ll le ey y
1, Lisa LaGuardia
1, Marcos Bonardi
1,
Grace Cheah
2, James Church
1, Jon Vogel
1, Mark Baker
2,
Carol A. Burke
3
1Department of Colon and Rectal Surgery; 2Department of Radiology; 3Department 
of Gastroenterology, Cleveland Clinic Foundation
B Ba ac ck kg gr ro ou un nd d: : Patients with familial adenomatous
polyposis (FAP) need prophylactic colectomy or
proctocolectomy to prevent colorectal cancer. The type,
techniques and timing of surgery are determined by
various aspects of their phenotype and genotype,
including the severity of the colorectal polyposis and
the possibility of intra-abdominal desmoid tumors. We
performed this study to see if computed tomographic
colonography (CTC) would be an efficient and reliable
way of assessing the status of the colon and the
abdominal contents in general, thus facilitating surgical
strategy in patients coming to surgery with FAP .
M Me et th ho od ds s: :   Patients 14 years old or older having their
index colonic surgery for FAP were eligible. After informed
consent patients underwent CTC within 24 hours of the
surgery. Results from CTC were recorded on a standard
datasheet and were compared with findings at
colonoscopy, pathologic inspection of the colon removed
at surgery, perioperative EGD, and the results of
intraoperative exploration of the abdomen.
R Re es su ul lt ts s: : 7 patients were enrolled, 6 male and 
1 female. Their mean age at diagnosis of FAP was 
28 years and at surgery was 30 years. No patient had
a cancer clinically, on colonoscopy or on CTC. The
polyposis burden is shown in the Table 1. No patient
had intra-abdominal or abdominal wall desmoids. 
3 patients had extracolonic findings seen only on CTC
while in 0 patients these were confirmed at laparotomy.
C Co on nc cl lu us si io on ns s: :   This pilot study shows that CTC is 
a valuable tool for the assessment of patients coming
to surgery with FAP , allowing assessment of both the
colon and the abdominal contents and potentially
affecting surgical strategy.
[22]
Ileal Polyp Formation Above Ileo-Rectal Anastomosis in Familial
Adenomatous Polyposis
Olivia Will, Ripple F. Man, Kay F. Neale, S Su us sa an n   K K. .   C Cl la ar rk k
The Polyposis Registry, St Mark’s Hospital, London, United Kingdom
K Ke ey y   w wo or rd ds s: :   familial adenomatous polyposis, extra-
colonic, ileum
B Ba ac ck kg gr ro ou un nd d: :   Macroscopic ileal polyps are very rare
in familial adenomatous polyposis prior to colectomy.
Increasingly, it is recognised that the ileoanal pouch can
develop adenomas following restorative proctocolectomy.
This is the first retrospective study of a similar pheno-
T Ta ab bl le e   1 1. .
A At tt te en nu ua at te ed d    M Mi il ld d S Se ev ve er re e C Co ol lo or re ec ct ta al l
F FA AP P p po ol ly yp po os si is s p po ol ly yp po os si is s c ca an nc ce er r
Optical colonoscopy 1 2 4 0
CTC 1 3 3 0
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menon occurring in the ileum above the ileorectal
anastomosis (IRA), in a large cohort of patients.
M Me et th ho od ds s: :   202 FAP patients undergoing 6 monthly
rectal surveillance following IRA were identified at 
St Mark’s Hospital, and endoscopy and pathology
reports were reviewed.
R Re es su ul lt ts s: :   There were 169 patients without ileal polyps,
and 33 with adenomatous polyps noted in the ileum
above the rectal anastomosis. Average time since IRA
was 13.2 and 20 years respectively (p<0.05). 80% of
polyps were mildly dysplastic, and the remaining polyps
had moderate dysplasia. 86% were under 5 mm in size,
but the largest polyp noted was 15 mm, which was
moderately dysplastic, and removed endoscopically. 
6 patients had >10 adenomas. Notwithstanding the small
sample size, there was no obvious genotype-phenotype
correlation, nor correlation with rectal polyp burden.
C Co on nc cl lu us si io on ns s: :   These findings support the hypothesis
that surgery triggers tumorigenesis in the FAP small
bowel, possibly in a time-dependent manner, due to
exposure to an altered environmental milieu. While
there are no reports of ileal cancers in the setting of
an IRA, the finding of larger dysplastic lesions suggests
that progression to cancer is theoretically possible.
Thus the ileum proximal to the IRA should be examined
as part of the surveillance of the rectum. Further study
of small bowel tumorigenesis in FAP may pinpoint
environmental triggers for adenoma formation.
F Fu un nd di in ng g: :   Olivia Will is supported by the St Mark’s
Polyposis Registry, and Cancer Research UK.
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The Importance of Continued Follow-Up and Cancer Genetic
Evaluation as Illustrated in a Family with Gardner’s Syndrome
J Je en nn ni if fe er r   S S. .   W Wi il lb bu ur r, Jessica L. Kent, Robert D. Legare
Cancer Risk Assessment and Prevention Program, Program in Women’s Oncology, 
Women & Infants’ Hospital/Brown University School of Medicine, 101 Dudley Street,
Providence, RI 02905
B Ba ac ck kg gr ro ou un nd d: : The scientific community continues to
rapidly discover cancer predisposition genes as well
as more accurately define the phenotypic features of
these syndromes. These advancements assist in the
molecular identification of high-risk families and
provide more effective and individualized medical
management. Therefore, continued follow-up becomes
critical and is exemplified by Family A, a case that had
been lost to follow-up for almost 40 years. Family A
was first reported in the literature in 1955 by Weiner
and Cooper, presenting with a dominant inheritance
pattern of osteomatosis, multiple soft tissue tumors and
colorectal adenomatosis polyposis consistent with
several families previously reported by Gardner et al.
between 1950 and 1953. The clinical diagnosis of
Gardner syndrome was then established. In 1969 Coli
et al. further described the phenotypic manifestations
of Family A’s second and third generations, after which
the family was largely lost to follow-up until two second
generation members presented to our high-risk clinic.
M Me et th ho od ds s: : An updated family history was collected
and compared to that previously reported in the
literature. As a result of the gynecologic tumors found,
a literature search was conducted evaluating the
frequency of this tumor type as an associated feature
of FAP/Gardner syndrome.
R Re es su ul lt ts s: : The four relatives counseled in our high-
risk clinic were educated regarding the appropriate
medical follow-up, as well as the fact that molecular
testing for Gardner syndrome is now available. The
only remaining relative clinically affected with Gardner
syndrome is awaiting his APC results. Due to the
presence of male breast cancer, female breast cancer
and ovarian cancer BRCA gene analysis was
performed in two affected women, which failed 
to identify a mutation. One of these women was 
also found negative for APC and MYH mutations. 
An updated pedigree revealed new cases of breast,
ovarian and primary peritioneal cancers in the second
and third generations. Additional tumors were also
reported which include a 39-year-old woman
diagnosed with a glioblastoma and a woman
diagnosed with a benign orbital mass and thyroid
tumor.
C Co on nc cl lu us si io on ns s: : The presence of multiple newly reported
cases of breast and ovarian cancers within Family A
raises concern for either two independent cancer
predisposition syndromes, hereditary breast and ovarian
cancer susceptibility syndrome (HBOCS) and familial
adenomatous polyposis (FAP) or the possibility for the
rare occurrence of gynecologic cancers within a Gardner
syndrome family. The latter has been previously reported
in a small case series and may be supported by the lack
of identifiable mutations on BRCA sequencing. The
dynamic changes in this pedigree underscore the
importance of continued follow-up for cancer families
in which the underlying etiology is unknown. Such
families should be followed in cancer genetics clinics to
update family histories, ensure that appropriate screening
regimens are followed, and to offer genetic testing if the
appropriate analysis becomes available.
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Novel Mutation in MSH6 and Adrenocortical Carcinoma
V Vi ir rg gi in ni ia a   J J. .   S Sp pe ea ar re e
1, Andrea G. Jordan
1, Mark A. Kaplan
1,
Wendy A. Conlon
2, Immanuel K. Ho
1
1Crozer Regional Cancer Center, Crozer Chester Medical Center, One Medical Center Blvd.,
Upland, PA 19013; 2Quest Diagnostics Nichols Institute, San Juan Capistrano, CA
K Ke ey y   w wo or rd ds s: :   Lynch syndrome, MSH6, adrenocortical
carcinoma
B Ba ac ck kg gr ro ou un nd d: :   Definition of the spectrum of cancers
associated with germline mutations in the mismatch
repair (MMR) genes is important for the accurate
counseling and management of high-risk families.
Lynch syndrome is associated with tumors of the colon,
endometrium, ovary and stomach. Tumors of other
organs, including the small bowel, urinary tract, gall
bladder, bile ducts and brain are rare, occurring in less
than 5% of individuals with Lynch syndrome. Rare
cancers such as adrenocortical carcinoma are not
considered part of the Lynch syndrome tumor spectrum.
Case reports of adrenocortical carcinoma in families
with inherited MSH2 mutations provide evidence both
for and against the association of this rare cancer with
MMR defects.
M Me et th ho od ds s: :   A 49-year-old female was referred for
hereditary cancer evaluation after a diagnosis of
moderately differentiated and partially mucinous
adenocarcinoma of the cecum. The patient had 
a history of thyroid cancer of unknown histological type
at age 25 years. Family history was significant for
endometrial carcinoma in the patient’s mother at 
40 years of age. Pre-screening for Lynch syndrome
included microsatellite instability (MSI) testing of the
tumor and immunohistochemical (IHC) staining for
MLH1, MSH2 and MSH6.
R Re es su ul lt ts s: : Results were MSI high and absent staining for
MSH6 protein with positive staining for MLH1 and MSH2
proteins. Germline testing revealed the novel frame shift
mutation c.3312insT in exon 5 of MSH6. In the course
of counseling and management, our patient’s 53-year-
old sister was found to have a large abdominal mass. 
A colonoscopy was negative and a hysterectomy had been
performed in the past for benign disease. Needle biopsy
of the mass revealed a poorly differentiated carcinoma
with IHC staining consistent with adrenocortical
carcinoma. IHC staining for MSH6 protein was negative
and the patient was found to carry the c.3321insT
mutation. MSI and loss of heterozygosity (LOH) studies
have not been performed to date.
C Co on nc cl lu us si io on ns s: : Our case provides further evidence
that an underlying MMR defect may be causative in
cases of rare cancers diagnosed in Lynch syndrome
families. In evaluating families for possible Lynch
syndrome, it is important to consider all cancers, as
defects in the cellular DNA repair system may contribute
to the etiology of a wider range of tumors than
previously thought.
[25]
Lynch Syndrome Mutation Prevalence in a Large Series of Patients
M Mi ic ch he el ll le e   M Ma ar rt ti in n
1, Lynn A. Burbidge
1, Cynthia Frye
1, 
Ben Roa, Richard Wenstrup
1
1Myriad Genetic Laboratories, Inc. 320 Wakara Way, Salt Lake City, UT 84108
K Ke ey y   w wo or rd ds s: :   Lynch syndrome, mutation prevalence,
genetic testing
B Ba ac ck kg gr ro ou un nd d: :   Deleterious mutations in the mismatch
repair genes MLH1, MSH2 and MSH6 are known to
cause Lynch syndrome (HNPCC). The aim of this study
was to measure the prevalence of these gene mutations
in groups of patients stratified by personal and family
history as reported on the test requisition form of 
a large commercial laboratory.
M Me et th ho od ds s: :   Myriad Genetic Laboratories offers full
sequencing and Southern blot of MLH1 and MSH2 for
detection of mutations causative of Lynch syndrome.
The more recent addition of MSH6 sequencing has
enhanced this analysis. For the current study, we report
the prevalence of mutations identified in our overall
test population and after stratification by personal and
family history.
R Re es su ul lt ts s: : Of 6,826 MLH1 and MSH2 gene analyses
performed, 916 (13.4%) patients were identified with
deleterious mutations. Of these patients, 388 had
mutations in the MLH1 gene, representing 42.4% of all
mutation-positive patients and 5.7% of the total tested
population. Five hundred twenty-eight (528) patients were
identified with a deleterious mutation in MSH2,
accounting for 57.6% of all mutation positive patients
and 7.7% of the total tested population. MSH6 gene
sequencing was performed on a total of 1247 patients;
39 (3.1%) patients had deleterious mutations. In patients
reporting a personal history of colorectal cancer (CRC)
under age 50 and no family history of Lynch syndrome
related cancers, the mutation prevalence was 7.2%
(22/306). Patients with CRC under 50 who reported 
a family history of at least one relative with a Lynch
syndrome cancer had a mutation prevalence in either
MLH1 or MSH2 of 26.5% (282/1064). Patients reporting
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related cancer and no family history had a mutation
prevalence of 8.8% (6/68). In patients reporting 
a personal history of more than one Lynch syndrome
related cancer and a family history of at least one family
member with a Lynch syndrome related cancer, the
mutation prevalence was 43.5% (161/370). Patients with
a personal history of endometrial cancer under the age
of 50 who report at least one family member with a Lynch
syndrome cancer, had a mutation prevalence of 29.6%
(45/152). In patients reporting a personal history of
ovarian cancer regardless of their family history (who may
or may not have relatives with Lynch syndrome related
cancers), we observed a mutation prevalence of 7.4%
(16/216).
C Co on nc cl lu us si io on n: : Patients with a personal and/or family
history of Lynch syndrome related cancers are appropriate
candidates for genetic testing of the mismatch repair
genes.
[26]
Survey of Cancers and Genotype-Phenotype Correlations in the Lynch
Syndrome Population at U.T. M.D. Andreson Cancer Center
T T. .M M. .   V Vu u
1, E. Salo
2, C.I. Amos
1, R.R. Broaddus
1, H. Northrup
3,
M.A. Rodriguez-Bigas
1
1University of Texas M.D. Anderson Cancer Center, Houston, Texas; 2St Joseph’s Regional
Medical Center, Paterson, New Jersey; 3The University of Texas Medical School at Houston,
Houston, Texas
B Ba ac ck kg gr ro ou un nd d: : Hereditary non-polyposis colorectal
cancer (HNPCC/Lynch syndrome) is an autosomal
dominant cancer predisposition syndrome caused by
germline mutations in mismatch repair (MMR) genes
– mainly hMLH1, hMSH2, hMSH6, and hPMS2. The
purpose of this study was to examine the prevalence
of cancers and evaluate genotype-phenotype
correlations in patients from a heterogeneous North
American patient population.
M Me et th ho od ds s: :   A retrospective medical record review was
performed on patients who, between February 1996 
and December 2006, underwent genetic counseling
evaluation for HNPCC, and/or whose tumors had
microsatellite instability (MSI-H), and/or loss of protein
expression on immunohistochemistry (IHC) analyses at
M.D. Anderson Cancer Center. Patients were classified
into three study groups according to their MMR gene
status.
R Re es su ul lt ts s: : Seventy-one patients had an MMR gene
mutation (mutation-positive group), 12 had a variant of
unknown significance (VUS group), and 40 had no
mutation clinically identified, but did have microsatellite
instability and/or abnormal immunohistochemistry protein
expression (mutation-negative group). hMSH2 alterations
were present in 50 mutation-positive patients and 6 VUS
patients; hMLH1 alterations were present in 18 mutation-
positive patients and 5 VUS patients; and hMSH6
alterations were present in 3 mutation-positive patients
and 1 VUS patient. Males were diagnosed with colorectal
cancer at an earlier age than females. Patients in the
mutation-positive group had the oldest age at sentinel
cancer diagnosis and oldest age at first colorectal cancer
diagnosis among the three study populations (p=0.0054;
p=0.0003). Individuals with non-truncating mutations
had a younger age at sentinel cancer diagnosis
compared to individuals with truncating mutations
(p=0.0488). An hMSH2 VUS (G683R) occurred
exclusively in patients of African American decent and
this may represent a population-specific mutation.
C Co on nc cl lu us si io on ns s: :   The results of this investigation suggest
that our study population elucidated both phenotypic
similarities and differences compared to what is
currently reported in the HNPCC literature. Further
studies evaluating large, heterogeneous North
American patient populations and mutation-specific
genotype-phenotype correlations are warranted.
F Fu un nd di in ng g: :   This research was supported, in part, by
a cancer prevention fellowship supported by the
National Cancer Institute to The University of Texas
M.D. Anderson Cancer Center’s Cancer Prevention
Research Training Program R25 CA56452, Robert M.
Chamberlain, Ph.D., Principal Investigator.
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